Renalytix PLC - London-based kidney health-focused diagnostics company - In the financial year to June 30, pretax loss narrows to USD46.2 million from USD49.6 million a year prior. Revenue grows 13% to USD3.4 million from USD3.0 million. Says that during financial 2023, over 5,000 KidneyIntelX tests were performed, up 55% annually. "We expect a meaningful increase in total tests during the remainder of fiscal 2024, building on quarterly test volumes of about 1,200 during fiscal 2023 and through first quarter of 2024. More than half of these during the first quarter of 2024 thus far are revenue generating, with a set of the Mount Sinai clinical trial tests no longer billable following last spring's transition to full commercial payment at the hospital system," the company says.
Current stock price: 66.50 pence, down 14% on Thursday
12-month change: up 13%
By Tom Budszus, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Renalytix Plc (RENX)